“This congress will provide you with a comprehensive overview of the critical issues shaping the future of Orphan Drugs and Rare Diseases.
In the United States, 1 in 10,000 people, or around 30 million Americans are affected by more than 10,000 known rare diseases.
According to reports (Fortune Business Insights), the global Orphan Drugs Market size is projected to reach USD 368.43 billion in 2030, at a CAGR of 11.6% during the forecast period, 2023-2030. Biological Orphan drug which has been use in treating rare diseases and in oncology therapy area possesses a substantially higher share in the global market as new cancer-related disease emerges and series of FDA approvals will result in increased commercialization of these drugs.
The two-day Congress aims to offer insights into how to improve the diagnostic process and access to treatments. Strategies and best practices, innovations, technologies and concepts that can promote rare diseases product development will be discussed in an interactive, thought-provoking and uplifting manner.”
+44 (0) 207 193 3485